Public health authorities outline who needs which vaccines, organized by age and other key variables—important information ...

The rivalry between Pfizer and MSD in pneumococcal vaccines has dialled up a notch with the FDA approval of MSD’s new shot Capvaxive, the first to be aimed specifically at adults. The 21-valent ...

The Centers for Disease Control and Prevention recommend that adults ages 65 or older receive the pneumococcal conjugate vaccination (PCV15 or PCV20). If you receive PCV15, it should be followed ...

Pneumococcal vaccination may reduce the risk for pneumonia-related morbidity and mortality among patients with immune-mediated inflammatory diseases.

Pneumococcal bacteria are present in the normal microbiome of the nose of many children and adults. In certain circumstances, ...

FDA drug alerts in pulmonology, including drug approvals/warnings, vaccine approvals, medical device recalls/updates, and ...

RSV or pneumococcal pneumonia. Vaccine hesitancy tends to skew younger, as adults aged 65 and older are the most likely to get the recommended immunizations. The nationwide survey was conducted by ...

Vaxcyte said its vaccine covers serotypes involved in around 95% of invasive pneumonia disease (IPD) cases in adults 50 and older in the US. It expects the pneumococcal vaccine market to reach a ...

Vaxcyte’s market potential is driven by $13.3B TAM in pneumococcal vaccine market, with potential FDA approval by late 2026 ...

influenza and pneumococcal vaccines, but they cannot bill for the other vaccines recommended by the Advisory Committee on Immunization Practices for older adult vaccines (Part D). “This ...

Vaxcyte said some doses of vaccine VAX-31 showed immune responses that exceeded expectations for 20 serotypes, or variations of the pneumococcal bacteria, which it had in common with Pfizer's Prevnar ...

The company, which does not have any approved product on the market, was testing the vaccine in 1,015 healthy adults aged 50 and above to prevent invasive pneumococcal disease. Jefferies analyst ...